-
- Highlights
- Preclinical studies at the Salk Institute laid the foundation for a question now being tested in patients: Can a vitamin D-based therapy “reprogram” a pancreatic tumor’s protective microenvironment, making tumors more vulnerable to therapeutic treatments?
- A clinical trial led by the Dana-Farber Cancer Institute now demonstrates that a synthetic vitamin D analog can be administered safely in combination with standard-of-care chemotherapy and effectively reprogram the supporting pancreatic tumor microenvironment.
- This work also provides early evidence that vitamin D analogs can enhance chemotherapy response and improve survival, especially in patients with high tumor vitamin D receptor expression.
LA JOLLA—A small clinical trial led by Dana-Farber Cancer Institute researchers put a Salk Institute idea to the test in patients: that activating the vitamin D receptor can help reshape the protective environment surrounding pancreatic tumors in ways that could make…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
